Preclinical study of pharmacokinetic ADME processes of phenosanic acid in vitro and in vivo

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


BACKGROUND: Phenosanic acid is a synthetic antioxidant, the active ingredient of the original domestic drug recommended for the treatment of epilepsy. To improve the effectiveness and safety of the use of phenosanoic acid, additional study of its pharmacokinetic properties is necessary.

AIM: To study the pharmacokinetic parameters of the active ingredient of the drug Dibufelon, capsule 200 mg (LLC “Piq-Pharma”, Russia) in vitro and in vivo systems in rats after single administration in one dose.

MATERIALS AND METHODS: Phenosanic acid binding to blood plasma proteins, microsomal stability and permeability through the monolayer of Caco-2 cells were evaluated in in vitro tests. The pharmacokinetics parameters were studied after a single intragastric administration in Wistar rats in dose of 80 mg/kg. The samples were analyzed by HPLC-UV.

RESULTS: A high variability in the degree of binding of phenosanic acid to blood plasma proteins by 20–65% depending on the concentration was revealed, relatively high microsomal stability (half-life — 1106 ± 789 min, internal clearance — 2.05 ± 0.86 μl/min/mg protein of liver microsome; residual content after 60 min incubation — 87.9 ± 7.8%) and the ability to penetrate through the monolayer of cells Caco-2. The rapid absorbtion of the substance into the systemic bloodstream was established — its maximum concentration in blood plasma was observed already 3.6 ± 1.2 hours after administration, and its slow removal from the systemic bloodstream — the half-life was about 19 h, the average retention time was about 29 h. Phenosanic acid with different degrees of intensity was distributed to all the examined organs and tissues: kidneys > liver > brain > omentum > muscle, and invariably excreted in a small amount with urine and feces, about 0.04% and 5.5%, respectively.

CONCLUSIONS: As a result of the study, it was found that phenosanic acid is characterized by rapid absorbtion into the systemic bloodstream and a long stay in it invariably, which may be due to the peculiarities of its binding to blood plasma proteins and relatively high metabolic stability, revealed during the corresponding in vitro tests. The study of the permeability and transport of phenosanic acid showed that it can presumably be attributed to compounds with medium permeability and is not a substrate for the transport protein P-glycoprotein (P-gp). The study of tissue availability of phenosanic acid confirmed its entry into peripheral tissues, including the brain, which is the area of implementation of the anticonvulsant effect.

Full Text

Restricted Access

About the authors

Vera M. Kosman

RMC “Home of Pharmacy”

ORCID iD: 0000-0001-9690-1935

Cand. Sci. (Med.), Head of Analytical laboratory

Russian Federation, 3/245, Zavodskaya st., Kuzmolovsky village, Vsevolozhsky district, Leningrad Region, 188663

Marina V. Karlina

RMC “Home of Pharmacy”

ORCID iD: 0000-0002-6292-8934

Cand. Sci. (Med.), Head of Department of technology, kinetics and analysis of drugs

Russian Federation, 3/245, Zavodskaya st., Kuzmolovsky village, Vsevolozhsky district, Leningrad Region, 188663

Ksenia V. Tyutina

RMC “Home of Pharmacy”

ORCID iD: 0000-0001-6037-204X

Junior Research Associate of Laboratory of immune-enzyme analysis

Russian Federation, 3/245, Zavodskaya st., Kuzmolovsky village, Vsevolozhsky district, Leningrad Region, 188663

Valery G. Makarov

RMC “Home of Pharmacy”

ORCID iD: 0000-0002-2447-7888

Dr. Sci. (Med.), Professor, Scientific Supervisor

Russian Federation, 3/245, Zavodskaya st., Kuzmolovsky village, Vsevolozhsky district, Leningrad Region, 188663

Marina N. Makarova

RMC “Home of Pharmacy”

ORCID iD: 0000-0003-3176-6386

Dr. Sci. (Med.), Director

Russian Federation, 3/245, Zavodskaya st., Kuzmolovsky village, Vsevolozhsky district, Leningrad Region, 188663

Sergey V. Morozov

LLC “Piq-Pharma”

ORCID iD: 0000-0002-8514-792X

Cand. Sci. (Med.), Development Director

Russian Federation, Moscow

Eugenia E. Gushchina

LLC “Piq-Pharma”

ORCID iD: 0000-0001-5138-5519

Medical Information Specialist

Russian Federation, Moscow

Natalia V. Zhuravskaya

LLC “Piq-Pharma”

Author for correspondence.
ORCID iD: 0000-0001-9586-4298

Head of Medical Department

Russian Federation, Moscow


  1. Burd SG, Lebedeva AV, Pantina NV, et al. Clinical results and prospects for the use of phenosanic acid in patients with focal epilepsy. Zhurnal Nevrologii i Psikhiatrii imeni SS. Korsakova. 2021;121(10):52–59. (In Russ.) doi: 10.17116/jnevro202112110152
  2. Altman DG, Bland JM. How to randomize. BMJ. 1999;319(7211):703–704. doi: 10.1136/bmj.319.7211.703
  3. Bland JM. An Introduction to Medical Statistics. 3rd edition. New York: Oxford University Press; 2000. 422 р.
  4. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–314. doi: 10.1016/j.cmpb.2010.01.007
  5. Prokopov AA, SHukil’ LV, Berlyand AS. Studying the bioavailability of fenozan acid in various medicinal forms. Khimiko farmatsevticheskii zhurnal. 2006;40(1):3–5. (In Russ.) doi: 10.30906/0023-1134-2006-40-1-3-5
  6. Kondratenko SN, Starodubcev AK, Belyakova GA. VEZHKH-opredelenie i farmakokinetika novogo original’nogo preparata Dibufelon®. Khimiko farmatsevticheskii zhurnal. 2009;43(11):54–56. (In Russ.) doi: 10.30906/0023-1134-2009-43-11-54-56
  7. Kosman VM, Karlina MV, Makarova MN. Experience in development of bioanalytical methods by HPLC with UV detection. Pharmacy. 2020;69(3):23–35. (In Russ.) doi: 10.29296/25419218-2020-03-04
  8. Luik AI, Luk’yanchuk VD. Syvorotochnyi al’bumin i biotransport yadov. Moscow: Meditsina; 1984. 224 p.
  9. Abaimov DA, Sariev AK, Noskova TYu, et al. Modern technologies in therapeutic drug monitoring (review). Epilepsy and paroxysmal conditions. 2013;5(2):31–41. (In Russ.)
  10. Mondal SK, Mazumber UK, Mondal NB, Banerjee S. Optimisation of rat liver microsomal stability assay using HPLC. J Biological Sci. 2008;8:1110–1114. doi: 10.3923/jbs.2008.1110.1114
  11. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27(11):1350–1359.
  12. Riley RJ, McGinnity DF, Austin RP. A Unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos. 2005;33(9):1304–1311. doi: 10.1124/dmd.105.004259
  13. Bohets H, Annaert P, Mannens G, et al. Strategies for absorption screening in drug discovery and development. Curr Top Med Chem. 2001;1:367–383. doi: 10.2174/1568026013394886
  14. Huebert ND, Dasgupta M, Chen Y. Using in vitro human tissues to predict pharmacokinet properties. Curr Opin Drug Discov Devel. 2004;7:69–74.
  15. Lennernas H, Palm K, Fagerholm U, Artursson. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. International Journal of Pharmaceutics. 1996;127:103–107. doi: 10.1016/0378-5173(95)04204-0
  16. Arena A, Phillips J, Blanchard M. MultiScreen Caco-2 Assay System. Drug transport assays in a 96-well system: reproducibility and correlation to human absorption. 2003. Available from:
  17. Marugan J.J., Xiao J., Zheng W., et al. ML223: A small molecule probe with in vivo activity against acute myeloid leukemia subtype M4Eo. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. 2010. Available from: Cited: 29 March 2022
  18. Zherdev VP, Kolyvanov GB, Litvin AA, et al. Garmonizaciya provedeniya issledovanij bioekvivalentnosti lekarstvennyh preparatov: voprosy i ih vozmozhnoe reshenie. Eksperimental’naya i klinicheskaya farmakologiya. 2003;66(2):60–64. (In Russ.) doi: 10.30906/0869-2092-2003-66-2-60-64

Copyright (c) 2022 ECO-vector LLC

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies